Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 19;11(5):457.
doi: 10.3390/v11050457.

Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies

Jun Inoue  1 , Takuya Nakamura  2 , Atsushi Masamune  3
Affiliations
Review

Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies

Jun Inoue et al. Viruses. .

Abstract

Reactivation of hepatitis B virus (HBV) is a major problem in patients receiving chemotherapy for malignant diseases or immunosuppression therapies. It has been thought that a reduction in the immune responses might result in the reactivation of HBV replication from covalently closed circular DNA (cccDNA) residing in hepatocytes. However, not only the host's immune status, but also viral mutations have been reported to be associated with reactivation. Especially, several case reports about amino acid mutations in hepatitis B surface antigen (HBsAg) that escape from immune reactions have been reported, and recent reports showed that the frequencies of such mutations are higher than previously expected. In this review, we summarize the characteristics of viral mutations, including immune escape mutations in HBV-reactivated patients, and discuss their significance.

Keywords: HBV; HBsAg; immune escape mutation; reactivation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dienstag J.L. Hepatitis B virus infection. N. Engl. J. Med. 2008;359:1486–1500. doi: 10.1056/NEJMra0801644. - DOI - PubMed
    1. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 1997;337:1733–1745. doi: 10.1056/NEJM199712113372406. - DOI - PubMed
    1. Schweitzer A., Horn J., Mikolajczyk R.T., Krause G., Ott J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555. doi: 10.1016/S0140-6736(15)61412-X. - DOI - PubMed
    1. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology. 2009;49:S156–S165. doi: 10.1002/hep.22945. - DOI - PubMed
    1. Das A., Maini M.K. Innate and adaptive immune responses in hepatitis B virus infection. Dig. Dis. 2010;28:126–132. doi: 10.1159/000282075. - DOI - PubMed

Substances